CA
NZ
UK
AU
IND
US
● Astrana Health reported second-quarterRevenueof $972.5 million, up 49% year over year, and raised full-year 2026 guidance to revenue of $4.1 billion and adjusted EBITDA of $280 million.
Biotech and health technology rarely move as a single block, and that is exactly the point. As of mid-September 2026, theNasdaqComposite houses companies at every stage of the healthcare life cycle, from profitable commercial franchises to pre-revenue clinical developers burning cash toward a first …
Biotech rarely moves as a single block, and this quintet proves it. Grouped only by their Nasdaq listing and their place in health innovation, CG Oncology (NASDAQ:CGON), Pasithea Therapeutics (NASDAQ:KTTA), GRAIL (NASDAQ:GRAL), AbCelleraBiologics(NASDAQ:ABCL) and Belite Bio (NASDAQ:BLTE) sit at wildly different points on the …
● Entera Bio closed a BVF Partners-led privatePlacementin July 2026 at $2.04 per share, extending its cash runway into 2030 ahead of a planned Phase 3 start for oral-peptide candidate EB613.
Biotech in 2026 is not one story but many, and this cluster captures the spread. On one end sit companies converting approvals into real, growing revenue; on the other, developers whose science may be promising but whose balance sheets are thin enough to threaten …
● Intelligent Bio Solutions submitted its FDA 510(k) package for the Intelligent Fingerprinting Drug Screening System on September 9, 2026, while carrying going-concern language and about $6.86 million in cash.
Healthcare is the most crowded neighborhood in theNasdaqComposite, and it is also the most fragmented. Within a single sector you can find a device maker scaling revenue at breakneck speed, a small pharma that just turned its first profit, a clinical-stage biotech living from …
Biotech in September 2026 is a market of two moods. Companies with approved products and real revenue are being rewarded for durability, while pre-revenue names live and die on single data points. Liquidia Corporation (NASDAQ:LQDA), RenovoRx (NASDAQ:RNXT), Krystal Biotech (NASDAQ:KRYS), Tenax Therapeutics (NASDAQ:TENX) and …
TheNasdaqComposite has always leaned on its technology giants, but underneath the megacaps sits a crowded field of clinical-stage biotech and health-technology names that trade on catalysts rather thanEarningsmultiples. September 2026 is a useful moment to look closely at five of them, because they span …
Grouping these five tickers together is an exercise in contrast, not comparison. IDEXX Laboratories is a multi-billion-dollar diagnostics compounder with a raised full-year outlook. The other four, Akari Therapeutics, Allarity Therapeutics, Aptevo Therapeutics and Revelation Biosciences, are clinical-stage micro-caps whose value rests on trial …
Please wait processing your request...